Hexylresorcinol

From Wikipedia, the free encyclopedia
  (Redirected from E586)
Jump to: navigation, search
Hexylresorcinol
Hexylresorcinol.svg
Hexylresorcinol-3D-balls.png
Systematic (IUPAC) name
4-hexylbenzene-1,3-diol
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
?
Identifiers
CAS number 136-77-6 YesY
ATC code R02AA12
PubChem CID 3610
ChemSpider 21106121 YesY
UNII R9QTB5E82N YesY
KEGG D04441 YesY
ChEMBL CHEMBL443605 YesY
Chemical data
Formula C12H18O2 
Mol. mass 194.27
 YesY (what is this?)  (verify)

Hexylresorcinol is an organic compound with local anaesthetic, antiseptic and anthelmintic properties.[1]

It is available for use topically on small skin infections, or as an ingredient in throat lozenges. Also Johnson & Johnson markets hexylresorcinol in its Neutrogena and RoC skincare products as an anti-aging cream.

A study published in Chemical Research in Toxicology [2] shows that 4-hexylresorcinol used as a food additive (E-586) exhibits some estrogenic activity, i.e. resembles action of the female sex hormone estrogen.

In one study, 4-hexylresorcinol increased the shelf life of shrimp by reducing melanosis (black spots).[3]

In mice with cancer, 4-hexylresorcinol inhibited NF-κB and extended their survival rate.[4]

References[edit]

  1. ^ O. Gisvold (1966). C. O. Wilson, O. Gisvold and R. F. Doerge, ed. Textbook of Organic Medicinal and Pharmaceutical Chemistry (5th ed.). Philadelphia: Lippincott. pp. 237–262. 
  2. ^ Amadasi, A; Mozzarelli, A; Meda, C; Maggi, A; Cozzini, P (2009). "Identification of xenoestrogens in food additives by an integrated in silico and in vitro approach". Chem. Res. Toxicol. 22 (1): 52–63. doi:10.1021/tx800048m. PMC 2758355. PMID 19063592. 
  3. ^ Montero, P. (2006). "Effectiveness of Onboard Application of 4-Hexylresorcinol in Inhibiting Melanosis in Shrimp (Parapenaeus longirostris)". Journal of Food Science. doi:10.1111/j.1365-2621.2004.tb09913.x. 
  4. ^ Kim, Seong-Gon (2011). "4-hexylresorcinol inhibits NF-κB phosphorylation and has a synergistic effect with cisplatin in KB cells". Oncology Report.